Clinical Trial Update: This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. [Phase 2]

View source ↗

Summary

This document reports a completed Phase 2 trial evaluating the efficacy and safety of ZD6474 in patients with non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ZD6474 (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line | Phase 2 | Status: COMPLETED